Prexasertib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	2	2	19	—	—	2010-02
Malignant Uterine Corpus Neoplasm	Phase2	Phase 2	1	1	1	—	—	Aug 29, 2022
Malignant Breast Neoplasm	Phase2	Phase 2	0	0	2	—	—	Jun 18, 2014
Malignant Lung Neoplasm	Phase2	Phase 2	0	0	3	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CHEK1 Overexpression1
Cisplatin + Olaparib

Clinical trials

Trials with this intervention (19)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–19 of 19 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05548296	A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma	recruiting	Phase 2	350	Acrivon TherapeuticsINDUSTRY	5	Aug 21, 2026	clinicaltrials
NCT06597565	A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC	recruiting	Phase 2	43	H. Lee Moffitt Cancer Center and Research Institute